Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Tonix Pharma ( (TNXP) ) has provided an update.
On July 10, 2025, Tonix Pharmaceuticals announced new findings on their TNX-801 vaccine candidate at the Vaccine Congress 2025. TNX-801, a recombinant horsepox-derived vaccine, shows promise in providing durable immunity against mpox and smallpox with a single dose. The vaccine is significantly less virulent than traditional smallpox vaccines and is effective when administered subcutaneously, potentially reducing side effects. Preclinical studies demonstrated robust immune responses in various animal models, including immunocompromised subjects. This development positions TNX-801 as a critical tool for public health preparedness against orthopox viruses.
The most recent analyst rating on (TNXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
Tonix Pharma’s overall stock score is driven by strong technical indicators and positive corporate events, which are partially offset by financial performance challenges and poor valuation metrics. The company’s growth potential in the biotechnology sector, supported by recent corporate developments, is a key strength.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. is a fully integrated biopharmaceutical company that focuses on developing therapies for pain management and vaccines for public health challenges. Its development portfolio includes treatments for central nervous system disorders, infectious diseases, and immunology, with a particular emphasis on fibromyalgia, mpox, and smallpox. The company operates a state-of-the-art infectious disease research facility and markets products for acute migraine treatment.
Average Trading Volume: 886,562
Technical Sentiment Signal: Sell
Current Market Cap: $261.6M
Learn more about TNXP stock on TipRanks’ Stock Analysis page.